Report of Foreign Issuer (6-k)
August 12 2020 - 4:52PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of August 2020
Commission File Number: 001-37643
KITOV PHARMA LTD.
(Translation of registrant’s name into
English)
One Azrieli Center, Round Tower, Tel Aviv
6701101, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file
annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F
☐
Indicate by check mark if the Registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the Registrant is
submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
On August 12, 2020, Kitov Pharma Ltd. (the
“Company” or the “Registrant”) issued a press release, “Kitov Pharma Announces ADS Ratio Change”,
which is attached hereto as Exhibit 99.1.
Exhibits
Incorporation by
Reference
This Form 6-K, including
all exhibits attached hereto, is hereby incorporated by reference into each of the Registrant’s
Registration Statements on Form F-3 filed with the Securities and Exchange Commission on December 12, 2016 (Registration file numbers
333-207117 and 333-211477), the Registrant’s
Registration Statement on Form S-8 filed with the Securities and Exchange Commission
on May 20, 2016 (Registration file number 333-211478), the Registrant’s Registration Statement on Form S-8 filed
with the Securities and Exchange Commission on June 6, 2017 (Registration file number 333-218538), the Registrant’s Registration
Statement on Form F-3, as amended, originally filed with the Securities and Exchange
Commission on July 16, 2018 (Registration file number 333-226195), the Registrant’s Registration Statement on Form
S-8 filed with the Securities and Exchange Commission on March 28, 2019 (Registration file
number 333-230584), the Registrant’s Registration Statement on Form F-3 filed
with the Securities and Exchange Commission on September 16, 2019 (Registration file number 333-233795), the Registrant’s
Registration Statement on Form F-3 filed with the Securities and Exchange Commission
on December 2, 2019 (Registration file number 333-235327), the Registrant’s Registration Statement on Form F-3 filed
with the Securities and Exchange Commission on May 13, 2020 (Registration file number 333- 238229), the Registrant’s Registration
Statement on Form S-8 filed with the Securities and Exchange Commission on May 28,
2020 (Registration file number 333-238481) and each of the Registrant’s Registration Statements on Form F-3 filed with the
Securities and Exchange Commission on July 10, 2020 (Registration file numbers 333-239807 and 333-233793), to be a part
thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed
or furnished.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
August 12, 2020
|
KITOV PHARMA LTD.
|
|
|
|
|
By:
|
/s/ Isaac Israel
|
|
|
Isaac Israel
|
|
|
Chief Executive Officer
|
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Sep 2023 to Sep 2024